Introduction Primary intracranial and sellar squamous cell carcinoma is an extremely rare entity, usually caused by malignant transformation of epidermoid cysts, or very rarely other non-malignant epithelial cysts. Malignant transformation of a Rathke's cleft cyst has never been described. Case Description We present a 49-year-old male patient who presented with a 3-month history of progressive frontotemporal headaches. Imaging revealed a 1.2 cm cystic pituitary mass consistent with a hemorrhagic Rathke's cleft cyst. The patient underwent trans-sphenoidal resection of the pituitary cyst, and pathologic analysis revealed a squamous cell carcinoma lining a Rathke's cleft cyst. Extensive imaging and otorhinolaryngologic evaluation revealed no primary source for metastasis. Conclusions We feel this represents the first case of a patient with a pituitary lesion in which presentation and MRI imaging were consistent with Rathke's cleft cyst, yet histology revealed squamous cell carcinoma in situ.
Introduction
Intracranial squamous cell carcinomas (SCCs) are typically manifestations of metastatic lesions from a primary focus outside the brain, or result from direct extension from the cranial base (secondary SCC). The third most common causes, albeit much rarer, is malignant transformation of a benign cyst (primary SCC) [1] . Those cysts are most commonly dermoid or epidermoid cysts, with extremely rare cases of malignant transformation of epithelial cysts, neuroepithelial cysts, endodermal cysts and craniopharyngiomas [1] [2] [3] [4] .
To the authors' best knowledge there have been no reports of SCC within a Rathke's cleft cyst (RCC). We present a very striking and atypical case of SCC within a RCC with no evidence of metastatic disease in an otherwise healthy patient. The patient was informed that data regarding his case would be submitted for publication.
Case report
A 49-year-old man presented to the hospital for worsening headache of 2 months duration. It was located frontally and did not abate with anti-allergic medications or two courses of antibiotics. After his headache worsened, a brain MRI revealed a 1.2 cm cystic pituitary mass consistent with a RCC versus hemorrhagic adenoma (Fig. 1) . The patient was evaluated by neurosurgery, neurology, and endocrinology. Visual fields were full to both confrontation and formal testing, and pituitary hormonal evaluation revealed only hypogonadotrophic hypogonadism in the setting of narcotics for headache (Table 1) . A CT scan showed no calcifications to suggest craniopharyngioma [5] .
The patient was subsequently discharged with a plan to control his pain and pursue surgical resection after resolution of pituitary hemorrhage. Over the next 3 months he had ongoing, unremitting headaches, and a repeat MRI confirmed an unchanged cystic lesion of the pituitary with proteinaceous contents. Four months after his initial presentation, the patient underwent uncomplicated trans-sphenoidal surgery to decompress the lesion and thereby treat his unremitting headache [6, 7] . Dissection of the pituitary revealed clear hemorrhagic fluid and a large portion of granular necrotic debris. Intraoperative fresh frozen sections revealed spindle cells and necrotic debris without obvious pituitary tissue.
On histopathologic analysis of the surgical specimen, (Fig. 2) there was loose myxoid fibrous tissue with extensive inflammation, including lymphocytes, histiocytes, and eosinophils. Fragments were focally lined by atypical squamous cells, which formed aggregates. Immunohistochemical staining of the lining epithelial cells was positive for p63, CK7, and cytokeratin cocktail and negative for chromogranin, MART-1, HMB 45, CK20, and TTF-1, thus establishing the diagnosis of a SCC lining the cyst. It could not be determined by pathologic appearance whether this squamous lesion represented a primary SCC or a metastatic SCC with subsequent cystic change.
The patient was referred to neuro-and radiation-oncology. An MRI of the C-, T-, and L-spine spine showed no evidence of metastasis. A PET-CT scan showed FDG-avidity around the surgical bed and the pharyngeal tonsils which, when inspected by ENT showed no squamous cell lesions. A 6-week course of focal stereotactic radiation therapy to the pituitary was recommended and performed without any immediate complications. To minimize chiasmal radiation, the target volume was treated to a cumulative dose of 5400 cGy with 30 fractions of 180 cGy each, delivered to the 82 % isodose. Follow-up MRIs at 3 and 6 months showed no evidence of recurrence. Additionally, a 1-year follow-up PET-CT and repeat MRI (Fig. 3) , showed no evidence of recurrent disease. His hypogonadotrophic hypogonadism and his headache resolved off narcotics. Despite being initially hormonally intact, he has subsequently developed central hypogonadism and hypothyroidism, which can be attributed to the adjuvant radiation. The patient remains otherwise asymptomatic and neurologically intact.
Discussion
Rathke's cleft cysts originate from the embryonic remnants of Rathke's pouch [8] . They are benign cystic lesions, located in the sellar and/or suprasellar region of the brain [9] . They are usually asymptomatic and found most commonly in autopsies, but an increasing number is found incidentally on brain imaging (CT or MRI) due to better availability and improvement in imaging techniques [10] . There is an [11] [12] [13] [14] [15] . Along the spectrum of sellar epithelial cysts, RCC is the most benign, behind craniopharyngiomas and dermoid/epidermoid cysts [16] . RCC is most often lined by simple cuboidal or columnar epithelium, with or without mucous-secreting goblet cells, and it is usually filled with a thick, mucoid material consisting of cholesterol and protein [8] [9] [10] 12] . Squamous metaplasia has been described in as many as 9-39 % of lesions and is associated with inflammation and cyst recurrence [16] . At higher risk for recurrence are also a minority of RCCs which are pathologically distinct by stratified squamous epithelium [7] . It has been proposed that this squamous metaplasia is caused by acute and chronic inflammation likely due to repeated cyst leakage or microhemorrhage [16, 17] .
There have been several case reports of primary intracranial SCCs, but there has never been a case of SCC originating from a RCC. The most common cause of intracranial SCC is by virtue of metastasizing from a cutaneous or nasopharyngeal primary carcinoma, or by direct extension of a carcinoma from the cranial base. A less common cause of intracranial primary SCC is via malignant transformation of a benign cyst [1] . Garcia et al. [18] have proposed the following criteria for this malignant transformation. The tumor has to be restricted to the intracranial, intra-dural compartment without extension beyond the dura, cranial orifices, or connection with the middle ear, air sinuses, or sella turcica. There should be no evidence of a nasopharyngeal tumor. Hamlat et al. [1] added two additional criteria: There must be evidence of a benign squamous cell epithelium within the malignant tumor mass. In addition, a nasopharyngeal tumor has to be ruled out. Hamlat epidermoid cyst, malignant transformation from a remnant epidermoid cyst, malignant transformation with leptomeningeal carcinomatosis, SCC arising from other benign cysts, other malignancies arising from benign cysts. Transformation of an epidermoid cyst has been described in the vast majority of such cases [19, 20] . There have been only few case reports of de novo intra-cranial SCC [21, 22] and malignant transformation of other non-neoplastic epithelial cysts. Those cysts include most commonly dermoid cysts, or more rarely epithelial cysts, neuroepithelial cysts, endodermal cysts and a craniopharyngioma [1, 3, [23] [24] [25] [26] . It seems that most cases arise at the cerebello-pontine angle, which is also the preferential site for epidermoid cysts.
In the present case, the presentation was subacute with unremitting headaches for a few months, and there was no clinical evidence of pituitary pathology. MRI findings were consistent with pituitary hemorrhage or hemorrhagic microadenoma or RCC. At the time of the surgery 3 months later, dissection of the pituitary revealed hemorrhagic fluid and a large portion of granular necrotic debris. As mentioned above, squamous metaplasia of a RCC has been described in multiple cases, with suggested mechanism of acute and chronic inflammation likely due to repeated cyst leakage or microhemorrhage [16, 17] . It is certainly possible that the patient had a RCC that underwent squamous metaplasia and subsequently malignant transformation to SCC. No prior imaging is available to confirm this hypothesis. On histopathologic examination, the tumor did not extend beyond the lining of the RCC. There was no evidence of a nasopharyngeal tumor by ENT inspection, despite FDG-avidity around the tonsils and the surgical bed on a PET-CT of the head and torso. There was also no evidence of another primary focus on an MRI of the C-, Tand L-spine at the time of diagnosis. Thus, the lesion was to the best of our observation not metastatic, though a metastatic cancer of unknown primary source cannot be ruled out. However an alternative primary SCC seems highly unlikely given that there is only one site involved in this patient and follow-up surveillance with yearly MRI of the head and spine, as well as PET-CT and nasopharyngeal inspection, for 3 years has not revealed any recurrent cancer or other source. Based on this evaluation, the tumor met the criteria by Garcia et al. for malignant transformation of a benign cyst.
Treatment of a symptomatic RCC is usually surgical, with the goal of the draining its content, and removal of the capsule [8] . Radiotherapy or radiosurgery has been used in a few cases of cyst recurrence with promising results. As malignant transformation of a RCC has never been described, there is no proposed treatment algorithm. However, it is well known that intracranial SCC has poor prognosis. More specifically, Hamlat et al. [1] reviewed 52 cases of SCC due to malignant transformation of epidermoid cysts, and most of the patients died within 12 months of diagnosis, with 12 patients being alive at the time of the review article and only one being alive after 5 years from diagnosis. Although not statistically significant, Hamlat et al. proposed that radiation therapy is likely beneficial, given a median survival of 26 months for the patients of their cohort who received radiation postoperatively, as compared to a median survival of 3 months for the patients who did not (p = 0.077). Based on this evidence, our patient received a 6-week course of focused radiation therapy to the pituitary. Subsequent 1-and 3-year follow-up PET-CT and MRI showed no evidence of recurrent disease.
More recently, Nagasawa et al. [27] reviewed 58 cases of malignant transformation of epidermoid cysts and compared different treatment options, including surgery alone, surgery plus multiple adjuvant treatments, stereotactic radiosurgery (SRS) and chemotherapy. There was no statistical significance in terms of the overall survival among SRS, chemotherapy or surgery plus multiple adjuvant treatments (at least 2), but there was statistically significant improved overall survival when comparing each of these treatment modalities with surgery alone. This review further supports the use of radiation as one possible treatment adjunct to surgery as in cases of malignant transformation of epidermoid cysts, and the present case suggests potential benefit from similar treatment modalities for rare cases of malignant transformation of RCCs.
Conclusion
Intracranial SCCs are rare tumors with a poor prognosis, and require a high index of suspicion and ultimately histopathological confirmation, as they do not have specific characteristics on imaging. Treatment of intracranial SCC is controversial due to the lack of outcome data which is due to insufficient cases reported in the literature-but there is sufficient evidence that adjuvant treatments to surgery should be used [27] . The authors suggest that the treatment of non-metastatic SCC within a RCC can be similar to the treatment of other types of non-metastatic intracranial SCCs.
